Sharekhan's research report on Abbott India
Operational profitability beat expectations; even as gross margin stayed flat y-o-y at 45.5%, EBITDA margin rose to a record high of ~25.5%, rising ~60 bps y-o-y. We believe Abbott’s strong market leadership in key therapies such as Women’s health, gastro and continuous double-digit product launches every year would continue to result in healthy operations. A 65% y-o-y rise in other income and 21% y-o-y fall in interest expenses led to ~18% y-o-y growth in PAT to Rs. 312.8 crore, 14% above our expectation of ~Rs. 274 crore.
Outlook
We maintain Buy with an increased PT of Rs 26,723. Stock currently trades at36.6.x/31.3x its FY2025E/FY2026E EPS.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Abbott India - 10 - 11 - 2023 - khan